| Literature DB >> 32411343 |
Caroline Knaut1, Carolina Bonfanti Mesquita1, Victor Zuniga Dourado1, Irma de Godoy1, Suzana E Tanni1.
Abstract
INTRODUCTION: Acute exacerbation is an important factor for a worse prognosis in patients with chronic obstructive pulmonary disease (COPD). It promotes the increase of the inflammatory process and worsens quality of life, lung function, and muscle weakness. It is believed that physical exercise performed during the exacerbation breaks the vicious cycle of systemic manifestations without an increase in the inflammatory process.Entities:
Year: 2020 PMID: 32411343 PMCID: PMC7204117 DOI: 10.1155/2020/6492720
Source DB: PubMed Journal: Int J Inflam ISSN: 2042-0099
Figure 1Flow diagram for patient inclusion in the study. PE, pulmonary thromboembolism; ICU, intensive care unit; Glasgow, coma scale.
Comparison of demographic and clinical characteristics at the baseline hospitalization according to control and intervention groups.
|
| Control group ( | Intervention group ( |
|
|---|---|---|---|
| Woman (%) | 69.2 | 61.5 | 0.70 |
| Age (y) | 69.3 ± 13.5 | 66.8 ± 9.49 | 0.58 |
| Smoking (pack-years) | 50.0 (31.8–92.0) | 46.0 (40.0–68.0) | 0.87 |
| LBMI (kg/m2) | 16.0 (14.8–17.0) | 15.7 (14.6–17.4) | 0.43 |
| BMI (kg/m2) | 23.3 ± 4.69 | 25.4 ± 5.29 | 0.41 |
| SGRQ | |||
| Symptom (%) | 72.8 ± 4.7 | 79.2 ± 4.5 | 0.52 |
| Activity (%) | 85.8 ± 3.9 | 91.5 ± 3.7 | 0.26 |
| Impact (%) | 46.5 ± 5.5 | 60.6 ± 5.3 | 0.44 |
| Total (%) | 62.7 ± 4.5 | 73.0 ± 4.3 | 0.53 |
| Anxiety, score | 7.4 ± 5.0 | 8.9 ± 6.9 | 0.89 |
| Depression, score | 5.3 ± 4.4 | 3.1 ± 3.1 | 0.04 |
| CRP (mg/dl) | 27.2 (7.30–50.52) | 8.35 (7.31–29.4) | 0.34 |
| TNF- | 1.57 (1.17–1.77) | 1.60 (1.07–1.69) | 0.64 |
| IL-6 (mg/dl) | 3.68 (1.60–7.10) | 2.01 (1.65–5.46) | 0.56 |
| FEV1 ( | 0.89 ± 0.32 | 0.75 ± 0.30 | 0.14 |
| FVC (%) | 60.1 ± 11.8 | 55.7 ± 17.0 | 0.55 |
| FVC ( | 1.82 ± 0.60 | 1.63 ± 0.52 | 0.28 |
| FEV1/FVC ( | 0.49 (0.47–0.56) | 0.45 (0.38–0.48) | 0.05 |
| PaO2 (mmhg) | 7.4 ± 0.0 | 7.4 ± 0.0 | 0.37 |
| PaCO2 (mmhg) | 56.1 ± 12.7 | 54.4 ± 14.7 | 0.83 |
| SaO2 (%) | 48.4 ± 5.2 | 47.7 ± 10.9 | 0.89 |
| BODE | 87.4 ± 4.8 | 84.8 ± 9.6 | 0.53 |
| 6MWD ( | 5.30 ± 1.88 | 6.53 ± 1.68 | 0.08 |
| 219.0 ± 136.8 | 190.7 ± 94.3 | 0.34 |
Values are expressed as mean ± standard deviation or median (quartile 1–quartile 3). LBMI, lean body mass index; BM,: body mass index; SGRQ, Saint George's Respiratory Questionnaire; CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, interleukin 6; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PaO2, arterial oxygen pressure; pH, hydrogenation potential; PaCo2, arterial pressure of carbon dioxide; SaO2, arterial oxygen saturation; BODE, body mass index, airway obstruction, dyspnea, and exercise capacity; 6MWT, six-minute walk test; p < 0.05, comparisons evaluated by the t test and Mann–Whitney test.
Evaluation of systemic inflammatory values before and after short-term aerobic exercise.
|
| Start of the test | End of the test |
|
|---|---|---|---|
| TNF- | 1.19 (0.99–1.71) | 1.21 (0.77–1.53) | 0.58 |
| IL-6 (mg/dl) | 2.41 (2.02–0.58) | 2.66 (1.69–0.48) | 0.21 |
| CRP (mg/dl) | 3.88 (2.26–8.04) | 4.07 (2.65–13.3) | 0.56 |
Values expressed as median (quartile 1–quartile 3). TNF-α, tumor necrosis factor alpha; IL-6, interleukin 6; CRP, C-reactive protein. p < 0.05, comparisons evaluated by the Wilkoxon test.
Comparison of evaluation moments and groups in relation to body composition, lung function, 6MWT, and BODE index.
|
| Control group ( | Intervention group ( |
|
|
| ||
| Hospitalization | After one month | Hospitalization | After one month | ||||
|
| |||||||
| BMI | 23.3 ± 4.4 | 24.2 ± 6.1 | 25.4 ± 4.8 | 26.5 ± 5.09 | 0.89 | 0.18 | 0.33 |
| LBMI | 16.0 ± 3.6 | 15.6 ± 6.8 | 15.7 ± 2.1 | 17.5 ± 2.1 | 0.36 | 0.45 | 0.38 |
| FEV1 (%) | 39.0 ± 9.6 | 40.4 ± 15.0 | 32.6 ± 15.2 | 40.9 ± 14.1 | 0.05 | 0.51 | 0.45 |
| FEV1 ( | 0.89 ± 0.29 | 1.02 ± 0.41 | 0.74 ± 0.32 | 0.91 ± 0.28 | 0.12 | 0.75 | 0.4 |
| FVC (%) | 60.1 ± 12.2 | 68.7 ± 18.2 | 55.7 ± 18.8 | 63.5 ± 18.5 | 0.09 | 0.89 | 0.55 |
| FVC ( | 1.82 ± 0.64 | 2.05 ± 0.78 | 1.63 ± 0.57 | 1.82 ± 0.51 | 0.23 | 0.87 | 0.49 |
| FEV1/FVC ( | 0.45 ± 0.09 | 0.50 ± 0.09 | 0.45 ± 0.09 | 0.50 ± 0.10 | 0.05 | 0.95 | 0.95 |
| BODE | 5.6 ± 1.9 | 5.0 ± 2.3 | 6.3 ± 1.7 | 4.4 ± 2.0 |
| 0.85 | 0.24 |
| 6MWT | 219.0 ± 38.4 | 269.5 ± 28.1 | 190.7 ± 40.3 | 277.4 ± 29.5 |
| 0.97 | 0.26 |
Values are expressed as mean ± standard deviation. LBMI, lean body mass index; BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 6MWT, six-minute walk test; BODE, body mass index, airway obstruction, dyspnea, and exercise capacity; p < 0.05, comparison evaluated by the two-way ANOVA test with repeated measures.
Comparison of evaluation moments and groups in relation to BDI, MMRC, and anxiety and depression.
|
| Control group ( | Intervention group ( |
|
|
| ||
|---|---|---|---|---|---|---|---|
| Hospitalization | After one month | Hospitalization | After one month | ||||
| BDI | 4.1 ± 3.0 | 5.6 ± 2.4 | 2.4 ± 1.6 | 5.0 ± 1.4 |
| 0.39 | 0.15 |
| MMRC | 2.7 ± 0.9 | 2.0 ± 1.0 | 3.1 ± 0.4 | 2.2 ± 0.6 |
| 0.24 | 0.67 |
| Anxiety | 7.4 ± 5.0 | 4.5 ± 5.4 | 8.9 ± 6.9 | 4.0 ± 4.9 |
| 0.80 | 0.60 |
| Depression | 5.3 ± 4.4 | 3.3 ± 3.9 | 3.1 ± 3.1 | 2.3 ± 2.2 | 0.22 | 0.17 | 0.63 |
Values are expressed as mean ± standard deviation. BDI, basal dyspnea index; P TxG, p value of the interaction between time and group. p < 0.05, comparison assessed by two-way ANOVA repeated measurements analysis.
Comparison of evaluation moments and groups in relation to SGRQ and dyspnea score.
|
| Control group ( | Intervention group ( |
|
|
| ||
|---|---|---|---|---|---|---|---|
| Hospitalization | After one month | Hospitalization | After one month | ||||
| Activity | 85.8 ± 3.9 | 63.0 ± 6.4 | 91.5 ± 3.7 | 66.3 ± 6.1 |
| 0.53 | 0.84 |
| Impact | 46.5 ± 5.5 | 31.7 ± 5.2 | 60.6 ± 5.3 | 31.8 ± 5.2 |
| 0.36 | 0.20 |
| Symptom | 72.8 ± 4.7 | 63.8 ± 4.7 | 79.2 ± 4.5 | 50.5 ± 4.5 |
| 0.38 |
|
| Total | 62.7 ± 4.5 | 47.9 ± 5.0 | 73.0 ± 4.3 | 44.5 ± 4.8 |
| 0.57 | 0.21 |
Values are expressed as mean ± standard deviation. SGRQ, Saint George's Respiratory Questionnairep < 0.05, comparison evaluated by the two-way ANOVA test with repeated measures.
Comparison of evaluation moments and groups in relation to systemic inflammation.
|
| Control group ( | Intervention group ( |
|
|
| ||
|---|---|---|---|---|---|---|---|
| Hospitalization | After one month | Hospitalization | After one month | ||||
| Log CRP (mg/dl) | 2.91 ± 0.64 | 2.15 ± 0.56 | 2.65 ± 0.54 | 2.48 ± 0.37 | 0.37 | 0.95 | 0.44 |
| logTNF-α (mg/dl) | 0.61 ± 0.14 | 0.66 ± 0.29 | 0.67 ± 0.22 | 0.32 ± 0.10 | 0.60 | 0.58 | 0.07 |
| Log IL-6 (mg/dl) | 1.30 ± 0.61 | 1.10 ± 0.12 | 1.40 ± 0.52 | 0.52 ± 0.74 | 0.30 | 0.99 | 0.34 |
Values are expressed as mean ± standard deviation. Log, transformed into logarithms; CRP, C-reactive protein. TNF-α, tumor necrosis factor alpha; IL-6, interleukin 6; P TxG, p value of the interaction between time and group. p < 0.05, comparison evaluated by the two-way ANOVA test with repeated measures.
Correlation of IL-6 levels with the independent variables.
| Variable dependent | Variables | Correlation |
|
|---|---|---|---|
| BDI | 0.50 | 0.07 | |
| 6MWD | −0.66 |
| |
| ΔIL-6 (%) | Symptom | −0.10 | 0.73 |
| Activity | −0.41 | 0.16 | |
| Impact | −0.02 | 0.94 | |
| Total | −0.15 | 0.60 |
IL-6, interleukin-6; 6MWD, six-minute walk test; BDI, basal dyspnea index. p < 0.05, comparison evaluated by the Pearson correlation test.
Correlation of TNF-α levels with the independent variables.
| Variable dependent | Variables | Correlation |
|
|---|---|---|---|
| BDI | −0.32 | 0.20 | |
| 6MWD | 0.09 | 0.70 | |
| ΔTNF- | Symptom | 0.23 | 0.36 |
| Activity | 0.47 | 0.05 | |
| Impact | 0.27 | 0.29 | |
| Total | 0.35 | 0.16 |
TNF-α, tumor necrosis factor alpha; 6MWD, six-minute walk test; BDI, basal dyspnea index. p < 0.05, comparison evaluated by the Pearson correlation test.
Correlation of PCR levels with the independent variables.
| Variable dependent | Variables | Correlation |
|
|---|---|---|---|
| BDI | 0.39 | 0.11 | |
| 6MWD | 0.33 | 0.18 | |
| ΔCRP (%) | Symptom | −0.20 | 0.42 |
| Activity | −0.05 | 0.82 | |
| Impact | −0.16 | 0.51 | |
| Total | −0.16 | 0.53 |
CRP, C-reactive protein; 6MWD, six-minute walk test; BDI, basal dyspnea index. p < 0.05, comparison evaluated by the Pearson correlation test.